Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration Sensitive Prostate Cancer”

170 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 170 results

Large-scale testing (Phase 3)Looking for participantsNCT03903835
What this trial is testing

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet 750
Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Large-scale testing (Phase 3)Ended earlyNCT04409288
What this trial is testing

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Chinese University of Hong Kong 74
Not applicableStudy completedNCT07428642
What this trial is testing

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Who this might be right for
Metastatic Hormone-Sensitive Prostate CancerProstate Cancer
First Affiliated Hospital of Wenzhou Medical University 168
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Not applicableWithdrawnNCT05245435
What this trial is testing

Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer

Who this might be right for
Prostate Cancer
Medical University of Vienna
Not applicableLooking for participantsNCT07172685
What this trial is testing

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Who this might be right for
Prostate Cancer
Qilu Hospital of Shandong University 116
Testing effectiveness (Phase 2)UnknownNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT04925063
What this trial is testing

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Who this might be right for
Metastatic Prostate Cancer
Sun Yat-sen University 266
Early research (Phase 1)Study completedNCT04477512
What this trial is testing

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Washington University School of Medicine 18
Large-scale testing (Phase 3)Looking for participantsNCT06931340
What this trial is testing

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology 1,260
Testing effectiveness (Phase 2)Looking for participantsNCT05422911
What this trial is testing

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Who this might be right for
Metastatic CancerNeoplasm, ProstateCastrate-sensitive+1 more
Sun Pharmaceutical Industries Limited 192
Testing effectiveness (Phase 2)WithdrawnNCT06060587
What this trial is testing

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Who this might be right for
Prostate Cancer
Northwestern University
Testing effectiveness (Phase 2)Looking for participantsNCT05914116
What this trial is testing

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
DualityBio Inc. 862
Not applicableStudy completedNCT02376296
What this trial is testing

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Saladax Biomedical, Inc. 35
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Large-scale testing (Phase 3)Not Yet RecruitingNCT07591467
What this trial is testing

Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer

Who this might be right for
BRCA-MutatedNeuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate CancerProstate Cancer
Gustave Roussy, Cancer Campus, Grand Paris 330
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Large-scale testing (Phase 3)Looking for participantsNCT06496581
What this trial is testing

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Who this might be right for
Prostate Cancer Metastatic
UNICANCER 500
Not applicableNot Yet RecruitingNCT07804030
What this trial is testing

AI-Assisted Patient Support in mHSPC

Who this might be right for
Metastatic Prostate Cancer
Fudan University 160
Next Page